Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.58 |
| ▸ | BTK | Q06187 | 4/20 | 0.58 |
| ▸ | JAK3 | P52333 | 3/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 4/20 | 0.54 |
| ▸ | ITK | Q08881 | 6/20 | 0.52 |
| ▸ | SYK | P43405 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.50 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | PLK4 | O00444 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | PAK4 | O96013 | 1/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263777 | 0.91 | EGFR (0.56) | EGFRBTKJAK3SCN9ABRD4 | |
| SCHEMBL12278931 | 0.89 | BTK (0.47) | EGFRBTKJAK3SCN9ABRD4 | |
| SCHEMBL271260 | 0.87 | SCN9A (0.52) | EGFRBTKJAK3SCN9ABRD4 | |
| SCHEMBL271021 | 0.87 | SYK (0.68) | EGFRBTKJAK3BRD4ITK | |
| SCHEMBL271387 | 0.83 | IRAK4 (0.59) | EGFRBTKJAK3BRD4ITK | |
| SCHEMBL270995 | 0.83 | BRD4 (0.61) | EGFRBTKJAK3BRD4ITK | |
| SCHEMBL20216213 | 0.83 | EGFR (0.77) | EGFRBTKJAK3BRD4ITK | |
| SCHEMBL271520 | 0.82 | AURKA (0.51) | EGFRBTKJAK3BRD4SYK | |
| SCHEMBL270949 | 0.81 | BRD4 (0.49) | BRD4SYKAURKAAXLSTK17A | |
| SCHEMBL21108821 | 0.80 | EGFR (0.78) | EGFRBTKJAK3BRD4ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | TARGEGEN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | EGFR 181/4885BTK 9/4885JAK3 3/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | EGFR 181/4885BTK 9/4885JAK3 3/4885 |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | JAK2, STAT5A, STAT5B | EGFR 4628/4885BTK 51/4885JAK3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.